Area of research
Cancer Research · Genetics
Research interest
Research interests include Breast Cancer Treatment Studies, BRCA gene mutations in cancer, Breast Implant and Reconstruction, and Cancer Treatment and Pharmacology.
Large language models-enabled digital twins for precision medicine in rare gynecological tumors
The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
Factors influencing role preferences in decision-making of healthy women with BRCA1/2 pathogenic variants: subanalysis from a randomised controlled decision coaching trial
PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer
Expert-Guided Large Language Models for Clinical Decision Support in Precision Oncology
Childhood, adolescent, and young adulthood cancer risk in <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant carriers
Calculating Future 10-Year Breast Cancer Risks in Risk-Adapted Surveillance: A Method Comparison and Application in Clinical Practice
COVID-19 in Gynäkologie und Geburtshilfe
Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk
Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens
Current landscape of hospital information systems in gynecology and obstetrics in Germany: a survey of the commission Digital Medicine of the German Society for Gynecology and Obstetrics
Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer.
PubMed 2023cited by 7position: middle
Data from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
Ärztliches „Sich Zeit nehmen“ befürwortet – Erste Ergebnisse der WAVES-Studie im Rahmen der Diagnosemitteilung Brustkrebs
Author Correction: Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Ncald as a Potential Predictive Biomarker for the Efficacy of Platinum-Based Chemotherapy in Ovarian Cancer
Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials
Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
Estimating the Breast Cancer Burden in Germany and Implications for Risk-based Screening
A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer
Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer
Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix
Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers